Member Info for Brighty1

"It is our hope that as we look to conclude our most comprehensive Nuvec® studies to date, we will be able to present Nuvec® as a viable delivery solution to vaccine developers".

" 2021 could turn out to be a pivotal year for N4 Pharma, as our various applications for Nuvec® advance to the point where we can engage further with potential collaborators and partners. In parallel we are also exploring other assets that could be complimentary to Nuvec®".

Very encouraging and hopefully a collaboration RNS is not too far away.

Good luck, Brighty

One of the key messages in the excellent RNS today ... "demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings". Some will recall the RNS in January which confirmed the forthcoming global opportunities for ODX, so this is very encouraging indeed from a commercial / revenue perspective.

Plus ..."Study indicates that vaccination programmes could benefit from determining an individual's antibody status both prior to and after vaccination"

· The AbC-19TM rapid antibody test was effective in demonstrating the immune response of patients to the first dose of the Pfizer-BioNTech COVID-19 vaccine.

· The study highlighted a differential immune response of two cohorts of patients: those previously infected with COVID-19 and those not infected; and

· Patients previously infected with COVID-19 showed a stronger immune response to the first dose of the Pfizer-BioNTech COVID-19 vaccine;

Good luck, Brighty

For those that doubt the magnitude of the UK testing strategy and its potential for ODX investors check this out. Good luck, Brighty
https://mobile.twitter.com/OffRecord2020/status/1364218616519024643

Exactly. It's always much more prudent to rely on RNS announcements and company tweets as part of your investment strategy. I'm looking forward to the news flow starting re UK Govt and global contracts. We are in for a sensational few months. Good luck all ODX long term investors. Brighty

It's probably also worth noting that the re-trace could be because IG are calling on clients with a position in approx 900 small caps to cover their margin by 3pm this Friday and to close all spread bet and Cdfs by the end of March. This is having an impact across many small cap shares currently. For those, such as myself, who don't trade shares in this way it presents a buying opportunity to buy more on the dips. Cash is king etc. It is something to be aware of and also another good reason to make sure your stop losses don't catch you out. That could be one of the reasons for the drop as it would seem crazy to be selling SNG now when we are quite clearly on the cusp of big news. Good luck, Brighty

Another factor in the drop could be that IG are calling for clients with a position in approx 900 small caps to cover their margin by 3pm this Friday and to close all spread bet and Cdfs by the end of March. This is having an impact across many small cap shares currently. For those, such as myself, who don't trade shares in this way it presents a buying opportunity to buy more on the dips. Cash is king etc. It is something to be aware of and also another good reason to make sure your stop losses don't catch you out. That could be one of the reasons for the slight re-trace as it would seem crazy to be selling Sareum now when we are on the cusp. Good luck, Brighty

Yes, with Government contracts in place once the RNS' start being issued the ODX share price today is going to look very very cheap indeed. When NCYT was able to announce its contract wins the share price soared. It's just a matter of time now. Good luck all ODX shareholders, Brighty.

Over the past 15 months that I've been invested in TXP I've noted that you normally get a re-trace pre the next piece of news, so i would say it is normal for this dip to happen. We know news is on the way. Good luck, Brighty

Agreed. I have 4p a share as my 2021 TYM target. I think we will actually exceed that. Today's RNS is further evidence that TYM is heading in the right direction. Good luck, Brighty

RMM, your combo theory mirrors what I've been mulling over for quite a while now. We know that SRA 737 Chk1 was synthesised with gemcitabine (Eli Lilly) with very encouraging results plus there's the Merck data released in June 2019, both of which created a great deal of excitement about the prospects of SRA 737. It is plausible that Merck or Lilly are waiting in the wings to take this on. What an amazing journey the Sareum share price would be on then. Good luck, Brighty

Not long to wait now for what is likely to be a very interesting update RNS from N4P. It's probably going to be next week or the following week. I Initially had Feb 22nd for the next RNS, according to my notes, but this might have slipped a few days. Anyway, according to the recent RNS it is imminent: "We look forward to providing a full update on all our work streams, including our oral and oncology work, when we publish our full year results for the year ended 31 December 2020 which is expected to be towards the end of February / early March." - Nigel Theobald CEO, RNS Jan 2021.
Good luck, Brighty

Certainly and interesting time for TYM.
From the Sanderson Capital website: "We appeal to the investor who is diligent, patient and rational. We focus our efforts on a single long-only programme, and we are dedicated to the preservation of our clients’ capital".
Good to see that they take a long term approach to investing.
Also, worth noting their US focus. "To allow for the more convenient and effective servicing and support of our predominantly US client-base, we also have a marketing and client service team based in the US".
Today's RNS shows great confidence in TYM.
Good luck, Brighty

If it is then this will rocket. Argo Blockchain ARB has risen from 3p to 300p. Good luck, Brighty

In answer to your question, BWNG has traditionally updated the stock market at the end of April or first week in May. e.g. the previous final results have been RNS'd on 20th April 2016, 27th April 2017, 26th April 2018, 2nd May 2019. In 2020 they put the results back due to Covid. Normally it's the end of April (ish). Good luck, Brighty

Exactly and as you say 100p not that far away now plus don't forget that at the start of January 2020 this was over 140p. I have over 150p as my 2021 target for BWNG and expect 200p+ within 12-18 months. Good luck, Brighty

It's a pivotal time for N4P. Just check out what Nigel Theobald has had to say recently:

"The receipt of the intention to grant the primary Patent in respect of Nuvec® for Europe is a key milestone” – Nigel Theobald CEO, RNS Jan 2021

"We are entering a pivotal time for the Company over the next six months and I look forward to providing further updates as each work stream progresses" - Nigel Theobald CEO, RNS Nov 2020

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions" - Nigel Theobald CEO, RNS Dec 2020

"We believe, to the extent that Nuvec® as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers". Nigel Theobald CEO, RNS Dec 2020

"It is also particularly important as discussions with potential collaborators continue. We look forward to providing a full update on all our work streams, including our oral and oncology work, when we publish our full year results for the year ended 31 December 2020 which is expected to be towards the end of February / early March." - Nigel Theobald CEO, RNS Jan 2021

Good luck, Brighty

Reviewing some of the updates that we could be hearing about soon (some of which I've highlighted below) and you start to understand why N4P's share price could quite easily be over 100p in the next few months.

* N4P’s research in to whether Nuvec® can generate COVID-19-specific antibodies in mice.

* N4P’s potential for Nuvec® as an oral vaccine delivery system.

* N4P’s Nuvec® data on the delivery of gene silencing cancer therapies

* N4P’s update on in vivo and in vitro tests to demonstrate that Nuvec® loaded with plasmid DNA (pDNA) and messenger RNA (mRNA) can stimulate an immune response.

* N4P’s “significant interest to multiple vaccine developers” re keeping the vaccine stable and at room temperature. i.e. Nuvec® as a delivery platform could provide the solution.

* Evotec update.

I'm looking forward to an update on those "discussions with potential collaborators". Good luck, Brighty

Don't forget ODX investors that we should also be hearing about "regulatory approvals in a total of 27 geographies" in "due course", according to the January RNS. Interestingly the NCYT share price moved very quickly indeed once UK and global contract wins were confirmed. It's just a matter of time now....Good luck, Brighty

In the 2017 RGP RNS they stated: "In due course we will hopefully have a well-developed proposal that shall reward our shareholders' patience and provide them with significant value" - Barry Richard Pettitt, Chairman/CEO at Ross Group. Maybe - at last - we are about to see some action here. Good luck, Brighty

The fact that both Kymab and Avacta have had such a phenomenal last 12 months (Kymab sold for over $1 billion and AVCT up from 13p to 215p with its SARS-CoV-2 Lateral Flow Antigen Test) is surely very good news for Sareum. i.e. Dr Owen clearly knows a winner when he sees one. Good to have him on board as Sareum rapidly evolves in to a major licencing / takeover prospect in 2021. Good luck, Brighty